12 January 2018
EMA/24202/2018
EMEA/H/C/002515

Public statement

Evarrest

Withdrawal of the marketing authorisation in the European Union

On 15 November 2017, the European Commission withdrew the marketing authorisation for Evarrest (human fibrinogen / human thrombin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Omrix Biopharmaceuticals N. V., which notified the European Commission of its decision to permanently discontinue the marketing of the product in the EU for commercial reasons.

Evarrest was granted marketing authorisation in the EU on 25 September 2013 for the treatment of haemostasis and as an adjunct to haemostasis in bleeding.

The European Public Assessment Report (EPAR) for Evarrest will be updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact